Island Pharmaceuticals Ltd. is a drug research and repurposing company, focused on developing preventative or therapeutic drugs for viral infections. The company is headquartered in Melbourne, Victoria. The company went IPO on 2021-04-13. The firm is focused on areas of unmet need for antiviral therapeutics to address infectious diseases. Its lead asset is ISLA-101, a drug with a safety profile being repurposed for the prevention and treatment of dengue2 fever and other mosquito (or vector) borne diseases. ISLA-101 has been shown to have activity against all four strains of dengue virus as well as other flaviviruses such as Zika virus, West Nile virus, and Yellow Fever virus, as well as Chikungunya virus. While ISLA-101 is an oral formulation, the Company is also considering alternative formulations, including a long-acting oral formulation and intravenous formulations for severe dengue infections. The firm operates a single segment, being research and development activities principally in the geographic regions of Australia and the United States. Its subsidiary is Isla Pharmaceuticals Inc.
Follow-Up Questions
Qui est le CEO de Island Pharmaceuticals Ltd ?
Dr. David Foster est le Chief Executive Officer de Island Pharmaceuticals Ltd, il a rejoint l'entreprise depuis 2020.
Quelle est la performance du prix de l'action ILPLF ?
Le prix actuel de ILPLF est de $0, il a decreased de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Island Pharmaceuticals Ltd ?
Island Pharmaceuticals Ltd appartient à l'industrie Pharmaceuticals et le secteur est Health Care
Quelle est la capitalisation boursière de Island Pharmaceuticals Ltd ?
La capitalisation boursière actuelle de Island Pharmaceuticals Ltd est de $NaN
